Skin, Hair & Aesthetic
Palmitoyl Tetrapeptide-7
Also known as: Matrixyl 3000 component
Mechanism & research context
Cosmetic peptide studied for IL-6 modulation in keratinocyte models; used in topical anti-aging blends.
Safety flags
0 flagsNo curator-recorded safety flags for this entry. Absence of recorded flags is not evidence of safety. Many peptides lack adequate human data.
Research papers
16 recordsCitation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.
-
· 2026 Open access
Screening and machine learning-based prediction of translation-enhancing peptides that reduce ribosomal stalling in <i>Escherichia coli</i>.
-
· 2026
Differentiating the Substrate Profiles of Inflammatory Caspases Using Extended Förster Resonance Energy Transfer-Based Peptide Substrates.
-
· 2026
Oxidative Peptide Backbone Cleavage by a HEXXH Enzyme during RiPP Biosynthesis.
-
· 2026 Open access
Uniform design-embedded predictions of (tetra-)peptide physicochemical properties.
-
· 2026
Biocatalytic Tetrapeptide Macrocyclization by Cryptic Penicillin-Binding Protein-Type Thioesterases.
-
· 2026 Open access
Evolution of a Strategy for the Unified Synthesis of Enteropeptin Sactipeptides.
-
· 2026 Open access
An Open-Label Study to Assess the Efficacy and Tolerability of a Multifunctional, 10-Peptide Face and Neck Serum to Address Skin Quality.
-
· 2026 Open access
A framework for the safety evaluation of peptides in cosmetics.
-
· 2026 Open access
Lubricin's Mucin Domain Has Strong Polyproline Type II Helical Character.
-
· 2025 Open access
Evolution of a Pyroptosis-Apoptosis crosstalk drives non-canonical inflammasome signalling
-
· 2025 Open access
Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review.
-
· 2025 Open access
Synergistic Effects of Injectable Platelet-Rich Fibrin and Bioactive Peptides on Dermal Fibroblast Viability and Extracellular Matrix Gene Expression: An In Vitro Study.
-
· 2025 Open access
Rapid and Efficient Radiolabeling of Short Peptides.
-
· 2025 Open access
Novel Cyclic Tetrapeptides as Neuraminidase Inhibitors from a Sponge-Associated <i>Penicillium</i> sp. SCSIO41035.
-
· 2025 Open access
Tetrapeptide from microbial coculture exhibiting a unique algicidal mechanism against Alexandrium fundyense.
-
Review · PubMed (NCBI) Live search link
PubMed literature search: Palmitoyl Tetrapeptide-7
Run importer to populate live PubMed records. This placeholder links to a live search.
Clinical trials
2 records-
Live search Live search
Live ClinicalTrials.gov search: Palmitoyl Tetrapeptide-7
Condition: See live results
Open on ClinicalTrials.gov ↗ -
NCT05932732 PHASE4 COMPLETED
A Phase IV Open-label Trial Assessing the Impact on Skin Quality, Hydration, and Barrier of Three (3) Hydrafacial Treatments in Adults of Fitzpatrick Skin Types I-VI
Condition: Cutis Laxa Facialis; Xeroderma
Sponsor: Austin Institute for Clinical Research
Open on ClinicalTrials.gov ↗
Doses reported in studies
0 recordsNo study-protocol dose records have been curated for Palmitoyl Tetrapeptide-7 yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.
Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.
These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of Palmitoyl Tetrapeptide-7, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.
Why this page does not list a dose for self-use
The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for Palmitoyl Tetrapeptide-7. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.
If this compound has an FDA-approved label
If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.
Questions worth bringing to a clinician
- What is the evidence for this compound in someone with my history?
- What are the realistic, regulator-reviewed alternatives?
- What would you monitor, and what would make you stop?
If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.